The objective of this study was to characterize the peptide-binding motif of the major histocompatibility complex (MHC) class II HLA-DR8 molecule included in the type 1 diabetes-associated haplotype DRB1*0801-DQA1*0401/DQB1*0402 (DR8-DQ4), and compare it with that of other diabetes-associated MHC class II alleles; DR8-bound peptides were eluted from an HLA-DR homozygous lymphoblastoid cell line. The repertoire was characterized by peptide sequencing using a LTQ ion trap mass spectrometer coupled to a multidimensional liquid chromatography system. After validation of the spectra identification, the definition of the HLA-DR8 peptide-binding motif was achieved from the analysis of 486 natural ligands, based on serial alignments of all possible HLA-DR-binding cores. The DR8 motif showed a strong similarity with the peptide-binding motifs of other MHC class II diabetes-associated alleles, HLA-DQ8 and H-2 I-A g7 . Similar to HLA-DQ8 and H-2 I-A g7 , HLA-DR8 preferentially binds peptides with an acidic residue at position P9 of the binding core, indicating that DR8 is the susceptibility component of the DR8-DQ4 haplotype. Indeed, some DR8 peptides were identical to peptides previously identified as DQ8-or I-A g7 ligands, and several diabetes-specific peptides associated with DQ8 or I-A g7 could theoretically bind to HLA-DR8. These data further strengthen the association of HLA-DR8 with type I diabetes.
Introduction
Major histocompatibility complex (MHC) class II (human HLA-II) molecules are transmembrane glycoproteins that present mostly exogenous peptides to CD4 þ T lymphocytes and are composed of an a-and a b-chain, in which the b-chain is highly polymorphic and the polymorphism of the a-chain varies between isotypes. In the case of HLA-DR molecule, the a-chain is essentially monomorphic.
Peptides bound to MHC-II are of variable length and interact with different pockets within the binding groove of the molecule. These pockets contain mostly polymorphic residues, making different alleles to bind a specific group of residues in each pocket. 1 Peptides bind with the corresponding pocket residues of the binding groove via specific interactions of the core residues at relative positions P1, 4, 6 and 9 (anchor residues). For every MHC class II allele, each pocket has a specificity for different residues, determining the binding affinity of the peptides. 2 The HLA-DR allele HLA-DR8 has been associated with the susceptibility to some autoimmune diseases [3] [4] [5] and the DRB1*0801 (DR8)-DQA1*0401/DQB1*0402 (DQ4) haplotype is, after the high-risk DR3 and DR4, the next most predisposing haplotype to type 1 diabetes (T1D). 6 The major susceptibility alleles are HLA-DQ2 and DQ8, of the DR3 and DR4 haplotypes, respectively, as well as their NOD mouse homologous, I-A g7 (ref. 7, 8) . The mouse I-A g7 and the human DQ2 and DQ8 diabetogenic class II MHC molecules, all share the expression of a non-Asp amino acid at position 57 of the b-chain, whereas most other MHC class II alleles contain a conserved Asp residue at this position. 9 The absence of Asp at b57 is related to the preference of these alleles for the binding of acid residues in the P9 pocket. [10] [11] [12] [13] This common feature, known to be involved in clinical disease 14, 15 is also found in HLA-DR8, with Ser at b57, but not in the DQ4 (DQA1*0401/DQB1*0402), molecule of the DR8 haplotype that has an Asp at b57.
The crystal structure of I-A g7 (ref. 16 ), DQ8 (ref. 17 ) and DQ2, 18 together with peptide-binding data and studies of naturally processed peptides selected by these T1D-associated molecules 12, 19 permitted the description of the peptide-binding motifs for these alleles. However, the HLA-DR8 peptide repertoire has only been partially described 20 and the binding motif remains unknown. In the present report, we define the DR8 peptide-binding motif from the analysis of 486 unique natural ligands, that are the physiological products of antigen processing and presentation. 11 Similar to other diabetogenic class II molecules, the main feature of the HLA-DR8 peptidebinding motif is that it binds peptides with acidic residues at the P9 pocket. Knowing whether a peptide would bind to a specific MHC molecule is useful for vaccine or antigen-specific therapy development to rapidly point those most likely MHC-binding peptides and to screen out those peptides that will not bind.
Results
Description of the repertoire of peptides bound to HLA-DR8 (DRA1*0101/B1*0801) Analysis of the DR8 peptide repertoire was carried out by sequencing the bound peptides by MDLC-mESI-ITMS/MS, using a LTQ ion trap mass spectrometer. Over 40 000 MS/MS spectra were acquired from two samples and the data were searched against a protein target/decoy human database. 21 The target/decoy strategy is based on the principle that incorrect matches have an equal probability of being derived from either the target or the decoy database. 22, 23 In contrast, spectra with relevant sequence information will match their corresponding sequence in the target database but not in the decoy database. Most peptides were present as 'peptide families' or 'nested sets', in which all the members share a common sequence with varying flanking residues along the C-and the N-termini, as is usual for MHC class II peptides. As a quality control, manual checking of at least one spectrum from each peptide family and all single spectra was done, after which a total of 486 different natural DR8 ligands were identified (Supplementary Table 1 , Supplementary Data). Peptides eluted from DR8 were grouped into 230 different sets, of which 124 were composed by a single peptide and 106 contained 2-34 different peptides. The distribution of peptide size was normal (Figure 1) , with sizes ranging from 9 to 43 amino acid length, most (88.7%) within the standard class II size range, 12 to 22 amino acids. 20, 24 Peptides were derived from 192 different source proteins from several cellular compartments. To avoid redundancy, the most common protein localization was used for proteins belonging to more than one cell compartment. As expected, source proteins followed a pattern common to other B-cell line repertoires; 25, 26 most of which were exogenous, membrane proteins or residents of the endocytic pathway, but there were also a significant number of proteins from the cytosol (30.7%), as well as the nucleus and other cellular organelles ( Figure 1) .
Definition of the HLA-DR8 binding motif Our method of predicting DR8 binding motif was based on the hypothesis that the different pockets are independent from the rest of the peptide-binding groove. 27, 28 Thus, once the binding specificity of a pocket has been determined, this can be common to other HLA-DR alleles with identical residues contributing to the pocket. 25, 27 As shown in Figure 2 , the b1 domain sequences of HLA-DR8 and -DR1 differ in 15 residues, none in the region where position 1 (P1) of the peptide is anchored. Consequently, peptides bound to DR1 and DR8 should contain the same aromatic or hydrophobic residues at P1 (Tyr, Phe, Trp, Leu, Ile, Ala, Val or Met) (http://www.syfpeithi.de/Scripts/MHCServer.dll/ FindYourMotif.htm). Therefore, we defined the peptide A frequency analysis of the amino acid residues occupying each of the nine core positions was performed, defining a frequency matrix that included all possible cores for each sequence without repeated sequences. Thus, from 486 peptides, 228 different central sequences were defined (always using the common sequence within a family of peptides). From these central sequences, 789 different P1-P9 cores (nonamers) were obtained to build the frequency matrix. This experimental frequency was normalized over the mean frequency of the same residue among human proteins.
This first matrix showed a clear preference for acid residues in P9 (28% of the nonamers) (Supplementary Figure 1) . Therefore, when more than one core was defined for a single sequence and only one had Asp or Glu at P9, this was selected and a new matrix was generated, limiting the number of nonamers to 512. A clear preference for Lys in position P6 or P4 was then observed, and cores with this feature were then selected for peptides with more than one core, to produce a new matrix. The remaining multiple-core peptides were then narrowed down based on of their best match to the previous matrix. At the end, a final matrix was generated with only one possible core for each sequence ( Figure 3 ). Figure 4 shows the frequency of every amino acid residue at each core position and their relative increase or decrease with respect to their abundance in the human proteome. The data showed that the most significantly increased frequencies corresponded to positions P1, P4, P6 and P9. P1 was mainly occupied by Phe and Tyr (7.2-and 10-fold increase); Lys was preferred in P4 and P6 (3.6-and 4.3-fold increase); and Asp and Glu in P9 (9.3-and 3.8-fold increase). In addition, some residues were increased in other positions: Ile was increased by 2.2-fold in P3 and Ala in P7 had a 2.5-fold increase, indicating preferred residues for non-anchor positions. Some amino acids were significantly decreased, such as Ser in P4, Leu in P6 and Ala, Lys and Leu in P9. Residues only significantly increased before Bonferroni correction ( Figure 3 ) were considered secondary residues.
Our results also showed that the main restrictive position of the DR8 binding groove was the pocket that harbored the P9 residue. Of the total sequences analyzed, 71% had a core with the correct P1 and an acidic residue at P9, as observed for other T1D-associated MHC alleles, I-A g7 (ref. 10) and DQ8. 12 As for I-A g7 and DQ8, this pocket also accepted Gln, Asn and Gly. 12, 27 The decrease of Arg, Lys and Pro at P9 confirmed previous the data for non-Asp b57 alleles, 27 suggesting that these amino acids at P9 would negatively interfere with the peptide binding to DR8. An interesting result concerned the positions P4 and P6, with a clear preference for Lys: 46% of the peptides had Lys at P4 or P6. Of these, 45% (21% of the total) had Lys at P4 and 55% (25% of the total) had Lys at P6. Interestingly, the presence of Lys at one of the two positions appeared to exclude the presence of Lys at the other position; no peptide with Lys at both P4 and P6 was identified. A further analysis of the frequency of residue combinations at positions P4, P6 and P9 showed that, although positions P4 and P6 appear to be related to each other, P9 did not seem to influence the residues bound to the other two positions. Thus, the percent of peptides with Lys at P4 or P6 was similar within peptides with or without Asp or Glu at P9. Figure 5 shows the selected models of the DR8-peptide complex with the lowest interaction energy. The melanotransferrin peptide FTVYGLLDKAQDLF, fitted the DR8 motif (Tyr at P1, Leu at P4, Lys at P6 and Asp at P9) with a good theoretical binding affinity and should therefore be a good binder. The second model, made with another putative good binder, peptide DEEFLIKIAAIDN from phosphatidylinositol 4-kinase type 2-beta, has the lowest interaction energy with a Lys at P4. The docking performed to automatically calculate the possible unions of DR8 with the peptide, confirmed our hypothesis, that is, the most stable union that localized the peptide inside the binding groove had the predicted P1-P9 residues. 
Modeling results
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These interactions between the peptide and the DR8 molecule were then calculated with the protein interaction calculator (PIC) software. Hydrogen bonds and additional hydrophobic and ionic interactions were detected that were capable of maintaining the peptide bound and hence, stabilize the complex (data not shown).
Discussion
This study provides the first characterization of the peptide-binding motif for HLA-DR8 (DRA1*0101/ DRB1*0801), part of an HLA haplotype associated with susceptibility to T1D. We have established a reliable method of analysis based on highly sensitive proteomics for the identification of a large number of peptides and based on the bioinformatics tools to efficiently analyze the peptide sequences. Although it has not been established which of the alleles of the haplotype involved (DRB1*0801(DR8)-DQA1*0401/DQB1*0402(DQ4)) gives susceptibility to the disease, our results suggest that rather than DQ4, the most likely susceptibility allele is DR8. Indeed the HLA-DR8 sequence contains a structural feature common to other T1D-associated human (DQ8, DQ2) or mouse (I-A g7 ) alleles, the absence of Asp at position 57 of the b-chain, not found in the DQ4 molecule. In addition, the results show a striking similarity between the peptide-binding motif for HLA-DR8 and that of the other T1D alleles, the dominance of acidic residues at the P9 position of the peptide core. This feature is also absent from the HLA-DQ4 peptide-binding motif. 29 An immortalized homozygous HLA-DR8 cell line carrying the T1D-associated HLA-DR8-DQ4 haplotype 6 was used for the analysis. There is little information about peptides binding DR8 and no concrete information about the peptide-binding motif. Up till now only 50 sequences including nested-set groups 20 and two T-cell epitopes have been published. 30, 31 The use of naturally processed peptides instead of synthetic peptides or phage display libraries for the identification of peptidebinding motifs to MHC II molecules have the main advantage that the peptides had been selected by the antigen-presenting cells during the antigen processing, where a number of cellular events influence peptide selection. 32 We sequenced 486 unique naturally processed DR8-bound peptides by MDLC-mESI-ITMS/MS. As expected, most proteins generating the ligands were from membrane compartments, including plasma membrane, golgi apparatus, endosomes, lysosomes, endoplasmic reticulum and secretion vesicles. Several peptides arose from cytosolic proteins, consistent with previous findings for other alleles. 25, 26 Despite the high polymorphism of the MHC class II bchain, the region comprising b81-b92 is common between most HLA-DR alleles, including DR8. This region forms the pocket in which position P1 of the peptide is anchored, permitting the assumption that DR8 will bind hydrophobic and uncharged residues in this position, as all alleles sharing this region do. All, but four, of the sequences contained at least one hydrophobic or aromatic residue that could be selected as P1. Thus, this feature was used to define the peptide core, as we had in the definition of the peptide-binding motif of RA-associated HLA-DR10. 25 Class II molecules have a dimorphism that has been conserved through evolution, defined by the presence or absence of Asp at position 57 of the DR or DQ b-chain. This dimorphism has been demonstrated to have a major role in the molecule's binding to particular peptides, showing a preference for acid residues in P9 by nonAsp57 alleles, including DR8. 33 Three of the T1D-associated alleles in mice and human, H-2I-A g7 DQ2 and DQ8, share this polymorphism, with Ser or Ala substituting Asp at b57, as in HLA-DR8 (Supplementary  Table 2 ). Thus, the characteristics of the P9 pocket of DR8, DQ8 and its mouse homolog I-A g7 are similar and, as a consequence, all preferentially bind peptides with acidic residues at this position. Similar to DQ8 and I-A g7 , no positively charged amino acids at P9 were found in the DR8 peptides. HLA-DQ2, also associated with T1D, contains a highly positively charged binding groove in which acid residues are favored not only at P9 but also at virtually all positions. 19 On the other hand, the DQ4 molecule (DQA*0401/DQB*0402) of the DR8 haplotype Figure 5 Models of HLA-DR8 complexed with two peptides. Electrostatic potential surface of DR8 (red region, negative; blue region, positive) with the peptides anchored by the residues that give less interaction energy. (a) DR8 binding the melanotransferrin peptide IFTVYGLLDKAQDLF (containing K at P6) and (b) DR8 with the phosphatidylinositol 4-kinase peptide DEEFLIKIAAIDN (containing K at P4). Putative hydrogen-bonding network (orange) between the peptide (gray), and the residues composed of the peptide-binding groove of HLA-DR8 are shown. The Lys residues at P4 and P6, respectively, are marked in yellow.
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has Aspb57, hence it will not have preference for an acid residue at P9. Therefore, the susceptibility to T1D of the DR8-DQ4 haplotype should be given by the DR molecule. Another interesting feature of the DR8 binding motif was the preference for Lys at the P4 or P6 positions, not shared by other T1D-associated alleles. The preference was however restricted, as the presence of Lys in one of the positions appeared to prevent the location of the same amino acid in the other. Thus, only one Lys was allowed in the center of the groove, relating pockets 4 and 6. In a previous report, the binding affinity of peptides to DQ8 was shown to be decreased if there was a Lys in position 6 or 4, 12 indicating that this is a specific feature of DR8 peptides that may limit a possible repertoire sharing.
MHC accounts for approximately 50% of the familiar risk for T1D. 34 The identity of the b57 residue is important both for disease susceptibility and protection: Ala, Ser or Val at b57 defines predisposing alleles such as DQ2, DQ8, I-A g7 and DR8, whereas Asp is found in protective allele DQ6. The structural explanation for the importance of b57 was obtained from the crystal structure of I-A k and I-A d where it was shown that Asp at b57 forms a salt bridge with an Arg at position 76 of the a-chain (homologous to position 79 on the DQa chain). This interaction was important for stabilizing the ab-chain complex and contributed to the integrity of the class II peptide-binding groove. 35 The absence of Asp at b57 resulted in the loss of the b57-a76 salt bridge, modifying the hydrogen bond network. Without the acid residue, the Arg at a76 shifted slightly to form a hydrogen bond with Leu at b53 and Ser at b57 via a buried water molecule. The result was the formation of a wider P9 pocket, permitting greater lateral freedom to the side chain of peptide residues. The lack of Asp57 not only gives the potential to interact with peptides containing acidic residues at P9 but also with T-cell receptors with a negatively charged CDR3b loop. 36 The relationship between DR8 and these alleles was further confirmed by analyzing the theoretical capacity of DR8 peptides to binding DQ8, I-A g7 and DQ2, using the MHC2Pred tool for prediction of promiscuous MHC class II binders (http://www.imtech.res.in/raghava/ mhc2pred/). Of the 216 DR8 sequences analyzed, 59 and 51%, respectively, were potential good binders to DQ8 and I-Ag7, using a very stringent threshold of 1. No theoretical binding of any peptide to DQ2 was found (data not shown). In addition, a number (n ¼ 30) of welldefined peptides from T1D autoantigens GAD65, HSP60, proinsulin and ICA69, restricted by I-A g7 DQ8 and DR4 (B1*0401), were equally analyzed. Half of the peptides (15/30), including 6/12 restricted by DR4, showed a perfect fitting to the DR8 motif (Supplementary Table 3 ). On the other hand, some of the peptides isolated from DR8 had previously been identified as DQ8 or I-A g7 ligands (5/486, see Supplementary Table 1 , Supplementary Data) (http://www.syfpeithi.de/Scripts/MHCServer. dll/FindYourMotif.htm).
The polymorphism at b57 applies to DR, DQ and mouse class II beta chains, but its relationship to T1D risk in humans is more evident within the DQ allele series. A dose effect of this polymorphism in relation to the risk of T1D has not been established, although the highest association corresponds to a haplotype without Asp57 in both DR and DQ b-chains (DRB1*0405/DQA1*0301-DQB1*0302) (ref. 6 ) and the highest protection to the DR15 haplotypes, with Asp57 in both DR and DQ b chains (DRB1*15/DQA1*0102-DQB1*06). However, the presence of only one DQ allele lacking Asp57 appears to be enough for susceptibility, as it is the case for DR3 and the other associated DR4 haplotypes (Supplementary  Table 2 ). In addition, two protective haplotypes (DRB1*0701/DQA1*0201-DQB1*0303 and DRB1*1401/ DQA1*0101-DQB1*0503) carry a non-Asp DR and an Asp DQ. The HLA-DR8 haplotype associated with the disease, DR8-DQ4, behaves differently. In this study, the absence of Asp at position 57 of the DR molecule appears to be sufficient for disease risk. The relative importance of DR vs DQ for peptide presentation in each haplotype is not known, but the two non-Asp protective DR alleles have a totally different P9 pocket, whereas the DR8 P9 pocket is virtually identical to DQ8. Therefore, it is the specific sequence of peptides bound to these molecules that appear to be most important in defining the disease risk resulting from the unique capacity of some non-Asp DQ and DR alleles to bind peptides with such highly specific sequence motif. No other structural evidence common to risk haplotypes and absent in protective ones was found within P9 pocket residues.
Our data stress the importance of the peptides presented by class II molecules associated with autoimmune disease and suggest that the same peptides could be presented by the different T1D-associated alleles to be recognized by disease-related T cells.
Materials and methods
Cell lines and antibodies FN86 is a HLA-DR8 homozygous lymphoblastoid cell line. It was generated in our laboratory by Epstein-Barr virus transformation of B lymphocytes from fresh blood of a DRB1*0801 homozygous donor by following standard procedure. 37 The complete HLA typing for the FN86 cells was: HLA-A*0301,*1101; B*0702,*4402; Cw*0102,*0702; DRB1*0801; DQB1*0402. Transformed cells were grown in roller bottles in RPMI (SigmaAldrich, St Louis, MO, USA) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), washed twice in cold phosphate-buffered saline and stored as frozen pellets at À801C until use. Anti-HLA-DRb mouse IgG2b mAb B8.11.2 was kindly provided by Dr F Koning, Department of Immunohematology, Leiden University, The Netherlands, was used for affinity chromatography.
Immunoaffinity purification of HLA-DR-peptide complexes Peptide-HLA-DR complexes were purified as described, 38, 39 with some modifications. Briefly, 10 (ref. 9) cells were lysed in 50 mM TrisHCl, pH 7.6, 150 mM NaCl, 0.5% Nonidet P40 (Surfact-Amps NP40, Pierce, Rockford, IL, USA) with protease inhibitors (Complete Protease Inhibitor Cocktail, Roche Diagnostics, Basel, Switzerland) at 4 1C for 1 h. Lysates were centrifuged for 15 min at 1500 g, and supernatants ultracentrifuged for 1 h at 100 000 g and precleared using Tris-blocked sepharose beads. HLA-II-peptide complexes from the lysate were purified by affinity chromatography using 1 ml sepharose bead columns with 5 mg purified mAb B8.11.2.
HLA-II-peptide complexes were eluted with 0.1% trifluoroacetic acid, following standard procedures.
Eluted class II-peptide mixtures were spun through 10 000-Da cutoff ultrafiltration filters (Centricon 10; Amicon, Beverly, MA, USA) and collected from the flow-through.
Liquid chromatography-mass spectrometry analysis Samples were evaporated to dryness, dissolved in 1 ml 1% trifluoroacetic acid and desalted using C18 solid phase extraction cartridges (3 ml, 15 mg support, Varian, Lake Forest, CA, USA). The desalted mixtures were concentrated to 5 ml and diluted to 40 ml with 1% formic acid. Samples were analyzed by multidimensional liquid chromatography electrospray tandem mass spectrometry (MDLC-mESI-ITMS/MS), using a linear LTQ ion trap equipped with a microESI ion source (ThermoFisher, San Jose, CA, USA). Peptide separations were performed on an Agilent 1200 HPLC system (Agilent Technologies, Barcelona, Spain) composed of a capillary pump, a binary pump, a thermostated microinjector and a microswitch valve. An ion exchange Zorbax Bio-SCX II column (3.5 mm, 35 Â 3 mm) was used for the first LC dimension. Absorbed peptides were eluted using seven salt steps of 0, 10, 25, 50, 100, 500 and 2000 mM ammonium acetate. A Zorbax 300SB-C18 preconcentration cartridge (5 mm, 5 Â 0.3 mm, Agilent Technologies) was used to concentrate and desalt each peptide fraction before the second LC dimension. Capillary reversedphase liquid chromatography was performed using a 10-cm long, 150-mm i.d. Vydac C18 column (Vydac, Deerfield, IL, USA). Separation was carried out at 1 ml min À1 using a linear acetonitrile gradient from 3 to 40% in 120 min (solvent A: 0.1% formic acid, solvent B: acetonitrile with 0.1% formic acid). The scan range for full MS was 400-2000 m/z. A full scan followed by eight MS/MS for the most abundant signals were acquired using the automatic data-dependent mode of the instrument. In order to minimize the redundant selection of precursor ions, dynamic exclusion was set to 1 MS/MS scan for each time window of 5 min.
Database search MS/MS fragmentation spectra were searched using SEQUEST (Bioworks v3.3, ThermoFisher) against a combined target/decoy database consisting of the Human UniProt database (SwissProt release 08/04/2008), to which its reversed or pseudo-reversed copy was appended. The decoy database was constructed by reversing the sequence of the proteins in the human SwissProt databases. Search parameters were: peptide mass tolerance, 2 Da; fragment tolerance, 0.8 Da; no enzyme restriction; static modifications, carbamidomethylated cysteine ( þ 57 Da); dynamic modifications, methionine oxidation ( þ 16 Da). Correct peptide sequence identifications were evaluated using both the Xcorr score from SEQUEST and the D value, which was calculated as described. 21 Correct identifications were those with scores within the area defining a false discovery rate of o1%.
Matrix generation
The core sequences of the peptides were identified using the software program Motifs 09, created by Dr Joaquin Abian (software available online at http://code.google. com/p/mhc-laia-motifs/). Fixing the amino acids at P1 (based on the similarity of the P1 pocket of most DR alleles), the software identified all the possible cores within the peptide list. The aligned core sequences generated a 20 Â 9 matrix with the percentage of every amino acid at each position. A statistical analysis was then performed as previously described. 40 Briefly, the frequency of each amino acid residue in a given peptide position was normalized against the mean frequency of that residue among the human proteins (http://www.ebi.ac.uk/integr8/StatsAminoPage.do?org ProteomeId ¼ 25), using the w 2 -test with Yates' correction. Bonferroni correction (P-value Â 20) was then applied. P-values of o0.01 before and after correction were considered significant.
Modeling of HLA-DR8 with peptide
The HLA-DR8-CLIP model was generated by homology with the PHYRE 41 and MODELLER 42 software, using another CLIP-MHC class II (1MUJ) structure as a template. In order to identify the interacting region of two peptides studied in this work (DEEFLIKIAAIDN from human phosphatidylinositol 4-kinase and FTVYGLLDKAQDLF from human melanotransferrin), the peptides were divided into nine amino acids length fragments. Using the FoldX [43] [44] [45] software, the core positions of the CLIP peptide were mutated to reproduce every one of these nine amino acid sequences. FoldX generated 10 different models considering different putative residues rotamers for each of the nine amino acid sequence. The energy of each model was calculated with FoldX, and the most energy-efficient was selected and minimized using the NAMD software. 46 Finally, the best nine amino acid sequence was selected. The final candidate for each of the two peptides were depicted using the CHIMERA software. 47 
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